Abstract
The antibacterial activity of ciprofloxacin (Bay o 9867) was compared with those of norfloxacin, nalidixic acid, trimethoprim-sulfamethoxazole, cefaclor, sisomicin and cefotaxime in in vitro and mouse protection studies. Approximately 300 clinical isolates of clinically important gram-positive and gram-negative species were used. The median MICs of ciprofloxacin against gram-positive and gram-negative bacteria ranged from ≤ 0.015–1 mg/l. Ciprofloxacin was 2–8 fold more active than norfloxacin and 100-fold more active than nalidixic acid. It also had a wider spectrum of activity against gram-positive organisms including even enterococci. No cross-resistance was observed between ciprofloxacin and ß-lactam antibiotics or aminoglycosides. Only acidic pH conditions decreased its activity. Ciprofloxacin showed rapid bactericidal action against organisms in both the logarithmic and stationary growth phases. In mouse protection studies (intraperitoneal infection) ciprofloxacin was significantly more effective than norfloxacin, ampicillin, trimethoprim-sulfamethoxazole, and also showed excellent activity against Pseudomonas infections.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Ito, A., Hirai, K., Inoue, M., Koga, H., Suzue, S., Irikura, T., Mitsuhashi, S.: In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrobial Agents and Chemotherapy 1980, 17: 103–108.
Shimizu, M., Takase, Y., Nakamura, S., Katae, H., Inoue, S., Minami, A., Nakata, K., Sakaguchi, Y.: AT-2266, a new oral antipseudomonal agent. In: Nelson, J. D., Grassi, C. (ed.): Current chemotherapy and infectious disease. American Society for Microbiology, Washington D.C., 1980, p. 451–454.
Sato, K., Matsuura, Y., Inoue, M., Une, T., Osada, Y., Ogawa, H., Mitsuhashi, S.: In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrobial Agents and Chemotherapy 1982, 22: 548–553.
Shimizu, M., Takase, Y., Nakamura, S., Katae, H., Minami, A., Nakata, K., Inoue, S., Ishiyama, M., Kubo, Y.: Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrobial Agents and Chemotherapy 1975, 8: 132–138.
Wise, R., Andrews, J. M., Edwards, L. J.: In vitro activity of Bay o 9867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrobial Agents and Chemotherapy 1983, 23: 559–564.
Bauernfeind, A., Petermuller, C.: In Vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. European Journal of Clinical Microbiology 1983, 2: 111–115.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1986 Springer Fachmedien Wiesbaden
About this chapter
Cite this chapter
Zeiler, HJ., Grohe, K. (1986). The In Vitro and In Vivo Activity of Ciprofloxacin. In: Neu, H.C., Reeves, D.S. (eds) Ciprofloxacin. Current Topics in Infectious Diseases and Clinical Microbiology, vol 1. Vieweg+Teubner Verlag, Wiesbaden. https://doi.org/10.1007/978-3-663-01930-5_3
Download citation
DOI: https://doi.org/10.1007/978-3-663-01930-5_3
Publisher Name: Vieweg+Teubner Verlag, Wiesbaden
Print ISBN: 978-3-663-01931-2
Online ISBN: 978-3-663-01930-5
eBook Packages: Springer Book Archive